medical sciences |
14 |
esophageal squamous cell carcinoma |
13 |
gastroenterology |
10 |
prognostic marker |
10 |
signal transduction |
10 |
tissue microarray |
10 |
tumor suppressor |
10 |
adult |
9 |
aged |
9 |
esophageal cancer |
9 |
neoadjuvant therapy |
9 |
aged, 80 and over |
8 |
epidemiology |
7 |
treatment outcome |
7 |
esophagectomy |
6 |
14-3-3σ |
5 |
alport's syndrome |
5 |
autopsy - methods |
5 |
biomarker |
5 |
blunt trauma |
5 |
chemoradiation response |
5 |
chemotherapy, adjuvant |
5 |
china |
5 |
cisplatin |
5 |
dyspepsia |
5 |
endoscopy |
5 |
esophageal cancer surgery |
5 |
esophageal carcinoma |
5 |
esophageal leiomyoma |
5 |
female |
5 |
fluorine-18-fluorodeoxyglucose |
5 |
gastroesophageal reflux |
5 |
hmgb1 |
5 |
humans |
5 |
liver laceration |
5 |
liver trauma |
5 |
middle aged |
5 |
minimally invasive autopsy |
5 |
mir-193b |
5 |
multiple injuries |
5 |
neoadjuvant chemoradiation |
5 |
non-operative management |
5 |
noncardiac chest pain |
5 |
penetrative trauma |
5 |
positron-emission tomography |
5 |
serum micrornas |
5 |
survival |
5 |
xpa |
5 |
acute inflammatory response |
4 |
antineoplastic agents |
4 |
antineoplastic combined chemotherapy protocols - therapeutic use |
4 |
bariatric surgery |
4 |
carcinoma, squamous cell - mortality - pathology - surgery - therapy |
4 |
carcinoma, squamous cell - mortality - pathology - therapy |
4 |
carcinoma, squamous cell - pathology - therapy |
4 |
cell survival |
4 |
cervical lymph node metastases |
4 |
chemotherapy |
4 |
cholecystectomy |
4 |
combined modality therapy |
4 |
cytokines |
4 |
cytology and histology |
4 |
esophageal neoplasms - mortality - pathology - surgery - therapy |
4 |
esophageal neoplasms - mortality - pathology - therapy |
4 |
esophageal neoplasms - pathology - therapy |
4 |
esophagectomy - methods |
4 |
gastrectomy |
4 |
gastric bypass |
4 |
hmga2 |
4 |
lymph node excision |
4 |
lymph nodes - pathology |
4 |
lymphatic metastasis |
4 |
male |
4 |
microarray |
4 |
natural orifice translumenal endoscopic surgery |
4 |
neck |
4 |
notes |
4 |
obesity |
4 |
oncology medical sciences |
4 |
palliative care - methods |
4 |
peg10 |
4 |
prognosis |
4 |
quality of life |
4 |
radiology and nuclear medicine pharmacy and pharmacology biology |
4 |
radiotherapy |
4 |
radiotherapy, adjuvant |
4 |
shank2 |
4 |
surgery |
4 |
thoracic neoplasms - pathology - therapy |
4 |
transvaginal surgery |
4 |
18f-fdg pet/ct |
3 |
barrett's esophagus |
3 |
bmi |
3 |
cd71 |
3 |
chemotherapeutic drug responses |
3 |
communicable diseases |
3 |
comparability |
3 |
diabetes remission |
3 |
esophagus |
3 |
foxo1 |
3 |
gastric dysplasia |
3 |
mir-1288 |
3 |
multimodality treatment |
3 |
natural orifice translumenal surgery (notes) |
3 |
natural orifice transluminal endoscopic surgery |
3 |
oesophageal |
3 |
oxygen carrier |
3 |
patient-reported outcomes |
3 |
percist |
3 |
peritoneoscopy |
3 |
physical activity |
3 |
population‐based study |
3 |
porcine model |
3 |
response evaluation |
3 |
sirna |
3 |
squamous cell carcinoma |
3 |
transanal endoscopic surgery |
3 |
transferrin receptor |
3 |
transrectal |
3 |
transvaginal cholecystectomy |
3 |
yq23 |
3 |
administration, oral |
2 |
anastomosis |
2 |
anastomosis, surgical - adverse effects |
2 |
antineoplastic combined chemotherapy protocols - administration & dosage - therapeutic use |
2 |
asia-pacific |
2 |
asian barrett's consortium |
2 |
boerhaave’s |
2 |
breast carcinoma |
2 |
breast neoplasms - drug therapy - secondary |
2 |
bronchial fistula - etiology |
2 |
capecitabine |
2 |
carcinoma - pathology - surgery |
2 |
cyclophosphamide |
2 |
cyclophosphamide - administration & dosage |
2 |
deglutition disorders - etiology - therapy |
2 |
deoxycytidine - administration & dosage - analogs & derivatives |
2 |
diagnosis |
2 |
esophageal adenocarcinoma |
2 |
esophageal neoplasms - pathology - surgery |
2 |
esophageal neoplasms - surgery |
2 |
esophageal perforation |
2 |
esophagectomy - adverse effects |
2 |
esophagectomy for esophageal cancer |
2 |
esophagogastric junction - pathology - physiopathology |
2 |
esophagus - cancer - treatment. |
2 |
evaluation studies as topic |
2 |
fluorouracil - analogs & derivatives |
2 |
foregut surgery |
2 |
gastric outlet obstruction - etiology - therapy |
2 |
idarubicin |
2 |
idarubicin - administration & dosage |
2 |
ischemic gastric conduit |
2 |
laparoscopic colorectal resection |
2 |
lardiac stab injury |
2 |
metastatic breast cancer |
2 |
mie |
2 |
minimally invasive surgical approach |
2 |
modern results |
2 |
neoplasm recurrence, local - complications - mortality - physiopathology |
2 |
non-insulin-dependent diabetes - surgery |
2 |
oesophageal cancer |
2 |
oesophagectomy |
2 |
oral fluoropyrimidine |
2 |
outcome |
2 |
palliation |
2 |
palliative care |
2 |
pathogenesis |
2 |
perforation |
2 |
perforation score |
2 |
pericardiocentesis |
2 |
postoperative complications |
2 |
postoperative complications - surgery |
2 |
prague criteria |
2 |
recurrent esophageal carcinoma |
2 |
self-expanding metallic stent |
2 |
sepsis |
2 |
squamous cell cancer |
2 |
stents - adverse effects |
2 |
stomach neoplasms - pathology - surgery |
2 |
subxiphoid pericardial window |
2 |
surgical |
2 |
surgical reconstruction |
2 |
survey |
2 |
survival rate |
2 |
thoracotomy |
2 |
tobacco |
2 |
transoesophageal echocardiography |
2 |
treatment experience |
2 |
ventricular septal laceration |
2 |
asian country |
1 |
atrophic gastritis |
1 |
current situation |
1 |
endoscopic resection |
1 |
esophageal neoplasm |
1 |
esophagogastric junction |
1 |
esophagogastric junction adenocarcinoma |
1 |
helicobacter pylori |
1 |
obese |
1 |
predictive factors |
1 |
stomach neoplasm |
1 |
time trend |
1 |
type 2 diabetes |
1 |